BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27835789)

  • 1. A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis.
    Liu W; Wang L; Liu J; Yuan J; Chen J; Wu H; Xiang Q; Yang G; Li Y
    Transl Oncol; 2016 Dec; 9(6):521-530. PubMed ID: 27835789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of multispectral imaging in quantitative immunohistochemistry study of breast cancer: a comparative study.
    Liu WL; Wang LW; Chen JM; Yuan JP; Xiang QM; Yang GF; Qu AP; Liu J; Li Y
    Tumour Biol; 2016 Apr; 37(4):5013-24. PubMed ID: 26537585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer histopathology image analysis: A comparative study of prognostic values of automatically extracted morphometric nuclear features in multispectral and red-blue-green imagery.
    Liu W; Qu A; Yuan J; Wang L; Chen J; Zhang X; Wang H; Han Z; Li Y
    Histol Histopathol; 2024 Jan; ():18715. PubMed ID: 38343355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer.
    Xiang QM; Wang LW; Yuan JP; Chen JM; Yang F; Li Y
    Exp Mol Pathol; 2015 Aug; 99(1):133-8. PubMed ID: 26102249
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of the HER2-low status on conditional survival in patients with breast cancer.
    Ma T; Liu C; Ma T; Sun X; Cui J; Wang L; Mao Y; Wang H
    Ther Adv Med Oncol; 2024; 16():17588359231225039. PubMed ID: 38249333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
    Livi L; Meattini I; Saieva C; Franzese C; Di Cataldo V; Greto D; Franceschini D; Scotti V; Bonomo P; Nori J; Sanchez L; Vezzosi V; Bianchi S; Cataliotti L; Biti G
    Cancer; 2012 Jul; 118(13):3236-43. PubMed ID: 22028054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
    Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
    Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
    Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
    Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer.
    You C; Li J; Zhi W; Chen Y; Yang W; Gu Y; Peng W
    J Transl Med; 2019 Jul; 17(1):182. PubMed ID: 31262334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
    Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
    Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
    Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
    Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.